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CRYSTALLIZATION AND STRUCTURE OF A 
PLANT PEPTIDE DEFORMYLASE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional of US. application Ser. No. 
11/542,989, ?led Oct. 3, 2006, Which claims priority to US. 
Provisional Application Ser. No. 60/835,823 ?led Aug. 4, 
2006, the entire contents of Which are herein expressly incor 
porated herein by reference. 
STATEMENTS REGARDING FEDERALLY 
SPONSORED RESEARCH 
The invention Was funded in part by Grant No. MCB 
MCB-0240165 aWarded by the National Science Foundation 
(NSF). The government may have certain rights in the inven 
tion. 
TECHNICAL FIELD 
This invention relates to the crystallization and structure of 
plant peptide deformylase and methods of using the structure. 
BACKGROUND 
Peptide deformylase (DEF; EC 3.5.1.88) is a metallopep 
tidase that catalyzes the removal of an N-formyl group from 
N-formyl methionine, Which is the initiating amino acid resi 
due for prokaryotically translated proteins. DEF is an essen 
tial enzyme and mutations, deletions, or insertions in the DEF 
gene, or inhibition of enzymatic activity, are lethal to prokary 
otic organisms. For decades DEF Was believed to be exclu 
sively restricted to prokaryotes because protein translation in 
eukaryotic organisms initiates With an unformylated 
methionine residue. The restriction to prokaryotic organisms 
and the essentiality of DEF have made this enzyme the 
molecular target of many research efforts directed toWards the 
development of broad-spectrum antibiotics, Which Would 
have little or no mammalian toxicity. In 2000 the existence of 
DEF in the chloroplasts of higher plants Was reported, and it 
Was also discovered that actinonin, a potent inhibitor of DEF, 
Was phytotoxic to all plant species. The lethality of actinonin 
to a Wide range of plants, including many agriculturally sig 
ni?cant Weed species, suggests that DEF is an essential and 
highly conserved enzyme in plants, and inhibitors targeting 
this enzyme could potentially serve as a neW class of broad 
spectrum herbicides as Well as selectable markers. 
Accordingly, plant peptide deformylase (DEF) polypep 
tides provide an attractive target for crystallization and struc 
tural studies Which can lead to the identi?cation and synthesis 
of neW broad-spectrum herbicides and selectable markers 
With high speci?city toWards plant DEF. 
SUMMARY 
Provided herein are crystalline forms of a peptide deformy 
lase, and atomic coordinates derived therefrom, useful for 
designing and identifying compounds that modulate the 
activity of the peptide deformylase. Accordingly, in one 
embodiment, a crystalline form of a polypeptide comprising 
the amino acid residues of SEQ ID N011, is provided. In some 
aspects, the crystalline form includes a structure character 
ized by tetragonal space group symmetry P412l2 and unit cell 
of dimensions a, b, and c. In some aspects, a is about 40 A to 
about 60 A, b is about 40 A to about 60 A, and c is about 120 
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A to about 160 A. In other aspects, 0t:[3:y:90°. In some 
aspects, the polypeptide is a peptide deformylase isolated 
from Arabidopsis Zhaliana. 
In some embodiments, the crystalline form includes a coor 
dinated metal ion selected from the group of consisting of Fe, 
Zn, and Ni, and any combination thereof. In one aspect, the 
metal ion is coordinated by amino acid residues Cys171, His 
213, and His217 of SEQ ID N011. 
In another embodiment, a crystalline form of a polypeptide 
including a structure de?ned by one or more structure coor 
dinates of Arabidopsis Zhaliana peptide deformylase amino 
acid residues Gly121, Gly123, Leu124, Gln128, Glu169, 
Gly170, Cys171, Leu172, His213, Glu214, His 217, and 
Tyr178 according to Table 1, is provided. In general, struc 
tures derived from these crystalline forms encompass struc 
tures having coordinates that differ by a root mean square 
deviation ofless than about 1.5 A, 0.75 A, or 0.35 A, or any 
deviation in this range, When superimposed on the non-hy 
drogen atom positions of the corresponding atomic coordi 
nates of Table 1. In some aspects, amino acid residues 
Gly121, Gly123, Leu124, Gln128, Glu169, Gly170, Cys171, 
Leu172, His213, Glu214, His217, and Tyr178 include the 
active site of the peptide deformylase. In some aspects, the 
polypeptide includes an amino acid sequence having at least 
75%, at least 85%, or at least 95%, or any percent in this 
range, amino acid sequence identity to SEQ ID N011. 
In other embodiments, a crystalline form of a polypeptide 
provided herein also includes a ligand complexed With the 
polypeptide. In some aspects, the ligand is a small molecule. 
In another embodiment, a crystalline form of a polypeptide 
that includes the amino acid residues of SEQ ID N011 and an 
atomic structure characterized by the coordinates of Table 1, 
is provided. 
In yet another embodiment, a machine-readable medium 
embedded With information that corresponds to a three-di 
mensional structural representation of a crystalline form of a 
polypeptide as provided herein. 
In one embodiment, a computer system including a data 
base containing information on the three dimensional struc 
ture of a crystalline form of an Arabidopsis Zhaliana peptide 
deformylase polypeptide and a user interface to vieW the 
information, is provided. In some aspects, the computer sys 
tem includes information related to diffraction data obtained 
from a crystalline form comprising SEQ ID N011. In other 
aspects, the computer system of includes information related 
to an electron density map of a crystal comprising SEQ ID 
N011. 
In another aspect, a computer system provided herein 
includes information related to the structure coordinates of 
Table 1 or homologous structure coordinates for the amino 
acid residues of SEQ ID N011 that have a root mean square 
deviation of non-hydrogen atoms of less than about 1.5 A, 
0.75 A, 0.35 A, or any percent in this range, When superim 
posed on the non-hydrogen atom positions of the correspond 
ing atomic coordinates of Table 1. 
In other aspects, a computer system provided herein 
includes information related to the structure coordinates for 
one or more amino acid residues Gly121, Gly123, Leu124, 
Gln128, Glu169, Gly170, Cys171, Leu172, His213, Glu214, 
His 217, and Tyr178 according to Table 1, or similar structure 
coordinates for the amino acids including a root mean square 
deviation of non-hydrogen atoms of less than about 1.5 A, 
0.75 A, 0.35 A, or any percent in this range, When superim 
posed on the non-hydrogen atom positions of the correspond 
ing atomic coordinates of Table 1. 
In another embodiment, a method of identifying a candi 
date compound that binds to the active site of Arabidopsis 
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Zhaliana peptide deformylase polypeptide, is provided. The 
method includes comparing the atomic structure of the com 
pound With a three-dimensional structure of a crystalline 
form of an Arabidopsis Zhaliana peptide deformylase 
polypeptide and computationally identifying a candidate 
compound for an ability to bind to the Arabidopsis Zhaliana 
peptide deformylase. In some aspects, the candidate com 
pound binds to the active site of the Arabidopsis Zhaliana 
peptide deformylase. In other aspects, comparing the atomic 
structure of the compound With a three-dimensional structure 
of a crystalline form of an Arabidopsis Zhaliana peptide 
deformylase polypeptide includes employing a computa 
tional means to perform a ?tting operation betWeen the com 
pound and at least one binding site of the peptide deformy 
lase. 
In some embodiments, the candidate compound identi?ed 
by a computational method provided herein can be synthe 
siZed and screened for the ability to bind a plant peptide 
deformylase in vitro or in vivo. In some aspects, the com 
pound is an herbicide. 
In another embodiment, a method of identifying a candi 
date compound that binds to the active site of Arabidopsis 
Zhaliana peptide deformylase polypeptide, is provided. The 
method includes comparing the atomic structure of the com 
pound With a three-dimensional structural representation of a 
crystalline form provided herein and computationally identi 
fying a candidate compound for an ability to bind to the active 
site of Arabidopsis Zhaliana peptide deformylase. 
In yet another embodiment, a method of computationally 
designing a candidate compound that binds to Arabidopsis 
Zhaliana peptide deformylase polypeptide, is provided. The 
method includes comparing the atomic structure of chemical 
entities, or fragments thereof, With a three-dimensional struc 
tural representation of a crystalline form of a polypeptide 
provided herein; identifying chemical entities capable of 
associating With the three-dimensional structural representa 
tion of a crystalline form of a polypeptide; and assembling the 
chemical entities, or fragments thereof, into a single molecule 
to provide the structure of the candidate compound. In some 
aspects, the candidate compound binds to the active site of 
Arabidopsis Zhaliana peptide deformylase. 
In another embodiment, a method of identifying a region of 
Arabidopsis Zhaliana peptide deformylase polypeptide that 
contacts a compound, is provided. The method includes 
obtaining X-ray diffraction data for a crystal of Arabidopsis 
Zhaliana peptide deformylase; obtaining X-ray diffraction 
data for a complex of a Arabidopsis Zhaliana peptide 
deformylase and the compound; subtracting the X-ray dif 
fraction data from the peptide deformylase With the X-ray 
diffraction data obtained from the complex to obtain the dif 
ference in the X-ray diffraction data; obtaining phases that 
correspond to X-ray diffraction data obtained for the peptide 
deformylase; correlating the data to generate a difference 
Fourier image of the compound; and locating the region of 
Arabidopsis Zhaliana peptide deformylase contacted by the 
compound. In some aspects, the compound is actinonin. 
In another embodiment, a method of modifying an inhibi 
tor of Arabidopsis Zhaliana peptide deformylase activity, is 
provided. The method includes obtaining a crystal including 
an Arabidopsis Zhaliana peptide deformylase polypeptide 
and an inhibitor; obtaining the atomic coordinates of the 
crystal; correlating the atomic coordinate data With one or 
more molecular modeling techniques; identifying at least one 
modi?cation predicted to effect the interaction of the inhibi 
tor With the polypeptide; and modifying the inhibitor based 
on the prediction. In one aspect, the modi?cation is a com 
puter generated modi?cation. In other aspects, the modi?ca 
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tion is a physical modi?cation made to the structure of the 
inhibitor. In one aspect, the crystal comprises the amino acid 
residues of SEQ ID NO:l. 
In other aspects, the one or more molecular modeling tech 
niques are selected from the group consisting of graphic 
molecular modeling and computational chemistry. In another 
aspect, obtaining the atomic coordinates of the crystal 
includes detecting the interaction of the inhibitor to one or 
more amino acid residues Glyl 2 l, Glyl23, Leul 24, Glnl28, 
Glul69, Glyl70, Cysl7l, Leul72, His2l3, Glu2l4, His2l7, 
and Tyrl78 of SEQ ID NO:l. 
The details of one or more embodiments of the disclosure 
are set forth in the accompanying draWings and the descrip 
tion beloW. Other features, objects, and advantages Will be 
apparent from the description and draWings, and from the 
claims. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1A depicts a polyacrylamide gel shoWing that limited 
trypsinolysis creates a core protein that retained activity and 
remained soluble in the absence of high salt concentrations. 
FIG. 1B depicts the amino acid sequence of the AtDEF 
peptide (SEQ ID NO: 1). 
FIG. 2A depicts a ribbon representation of crystallized 
AtDEF2. The cylinders represent helices and the arroWs rep 
resent sheets. 
FIG. 2B depicts a slab vieW of the ribbon representation of 
trypsinolyZed AtDEF2 highlighting the active-site-metal 
binding ligands (l Cys and 2 His) from motifs II and III, 
respectively (EGCLS (SEQ ID NO: 15) and QHEXXH (SEQ 
ID NO: 16)). 
FIG. 3 depicts a graph of substrate speci?city comparison 
of AtDEFl and AtDEF2. 
FIG. 4 depicts a comparison of amino acid sequence con 
servation of the three motifs in AtDEFl and 2 and bacterial 
DEFs (SEQ ID NOS: 2-5). 
FIG. 5 depicts a molecular model of the N-terminal resi 
dues from the D1 polypeptide docked into the active site of 
Arabidopsis Zhaliana peptide deformylase. 
FIG. 6 depicts a phylogenetic analyses comparing Motif l 
(SEQ ID NO: 6), Motif 2 (SEQ ID N017) and Motif 3 (SEQ 
ID NO: 8) of plant AtDEFl peptide deformylase With the 
amino acid sequence of otherpeptide deformylase sequences. 
FIG. 7 depicts a phylogenetic analyses comparing Motif l 
(SEQ ID NO: 9), Motif2 (SEQ ID NO: 10) and Motif3 (SEQ 
ID NO: 11) of plant AtDEF2 peptide deformylase With the 
amino acid sequence of otherpeptide deformylase sequences. 
FIG. 8 depicts a phylogenetic analyses comparing Motif l 
(SEQ ID NO: 12), Motif 2 (SEQ ID NO: 13) and Motif 3 
(SEQ ID NO: 14) of various peptide deformylase amino acid 
sequences. 
Like reference symbols in the various draWings indicate 
like elements. 
DETAILED DESCRIPTION 
Provided herein are novel crystalline forms of peptide 
deformylase polypeptides and atomic coordinate information 
related to such crystals. Also provided are methods of using 
such information to identify, design and/or modify com 
pounds that modulate the activity of a peptide deformylase. In 
addition, computer systems that include such information are 
provided. The crystal structures and information derived 
therefrom are suitable for designing and identifying, for 
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example, broad spectrum herbicides. Such herbicides can be 
used, for example, to inhibit or prevent the growth of unde 
sirable vegetation. 
The crystal structure is based, at least in part, on the dis 
covery of a plant nuclear gene that encodes a chloroplast 
targeted peptide deformylase polypeptide. The gene has sub 
stantial homology to bacterial peptide deformylase. The 
deduced translation of this nucleic acid sequence reveals the 
presence of three conserved protein motifs associated With 
prokaryotic peptide deformylase (see e.g., FIGS. 6, 7, and 8). 
Nucleic acid and amino acid sequences for plant peptide 
deformylases are disclosed in US. Pat. No. 6,730,634, issued 
May 4, 2004, and US. Patent Application Publication No. 
20040088755, the contents of Which are incorporated herein 
by reference. 
It is to be understood that the crystalline form of a plant 
peptide deformylase from Which the atomic structure coordi 
nates of the invention can be obtained is not limited to Wild 
type Arabidopsis Zhaliana peptide deformylase polypeptide, 
or a truncated form of the polypeptide (see e.g., SEQ ID 
NO: 1) as provided herein. Indeed, the crystals may comprise 
mutants of Wild-type Arabidopsis Zhaliana peptide deformy 
lase or the sequence of amino acids set forth in SEQ ID NO:1 . 
Mutants can be obtained by replacing at least one amino acid 
residue in the sequence of the Wild-type Arabidopsis Zhaliana 
peptide deformylase or the sequence of amino acids set forth 
in SEQ ID NO:1 With a different amino acid residue, or by 
adding or deleting one or more amino acid residues Within the 
Wild-type sequence and/or at the N- and/ or C-terminus of the 
Wild-type Arabidopsis Zhaliana peptide deformylase or the 
sequence of amino acids set forth in SEQ ID NO:1. Prefer 
ably, such mutants Will crystallize under crystallization con 
ditions that are substantially similar to those used to crystal 
liZe the Wild-type Arabidopsis Zhaliana peptide deformylase 
or the sequence of amino acids set forth in SEQ ID NO:1. 
The types of mutants contemplated by this invention 
include conservative mutants, non-conservative mutants, 
deletion mutants, truncated mutants, extended mutants, 
methionine mutants, selenomethionine mutants, cysteine 
mutants and selenocysteine mutants. A mutant may have, but 
need not have, Arabidopsis Zhaliana peptide deformylase 
activity. Preferably, a mutant displays biological activity that 
is substantially similar to that of the Wild-type polypeptide or 
that of SEQ ID NO:1. 
It Will be recogniZed by one of skill in the art that the types 
of mutants contemplated herein are not mutually exclusive; 
that is, for example, a polypeptide having a conservative 
mutation in one amino acid may in addition have a truncation 
of residues at the N-terminus. 
In addition, conservative or non-conservative amino acid 
substitutions can be made to amino acids of Wild-type Ara 
bidopsis Zhaliana peptide deformylase or the sequence of 
amino acids set forth in SEQ ID NO:1 that are implicated in 
the active site of the polypeptide (e.g., amino acid residues 
Glyl2l, Gly123, Leu124,Gln128,Glu169, Gly170,Cys171, 
Leul72, His213, Glu2l4, His2l7, and Tyrl78 of SEQ ID 
NO: 1). Such conservative or non-conservative substitutions 
can affect, e.g., the a?inity With Which wild-typeArabidopsis 
Zhaliana peptide deformylase or the sequence of amino acids 
set forth in SEQ ID NO:1 binds to a substrate. In certain 
embodiments, the conservative or non-conservative amino 
acid substitutions can increase the a?inity With Which Wild 
type Arabidopsis Zhaliana peptide deformylase or the 
sequence of amino acids set forth in SEQ ID NO:1 binds to a 
substrate. 
Conservative amino acid substitutions are Well-knoWn in 
the art, and include substitutions made on the basis of a 
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similarity in polarity, charge, solubility, hydrophobicity and/ 
or the hydrophilicity of the amino acid residues involved. 
Typical conservative substitutions are those in Which the 
amino acid is substituted With a different amino acid that is a 
member of the same class or category, as those classes are 
de?ned herein. Thus, typical conservative substitutions 
include aromatic to aromatic, apolar to apolar, aliphatic to 
aliphatic, acidic to acidic, basic to basic, polar to polar, etc. 
Other conservative amino acid substitutions are Well knoWn 
in the art. It Will be recogniZed by those of skill in the art that 
generally, a total of about 20% or feWer, typically about 10% 
or feWer, most usually about 5% or feWer, of the amino acids 
in the Wild-type polypeptide sequence can be conservatively 
substituted With other amino acids Without deleteriously 
affecting the biological activity and/or three-dimensional 
structure of the molecule, provided that such substitutions do 
not involve residues that are critical for activity. The folloW 
ing abbreviations are used for amino acids throughout this 
disclosure: A:Ala:Alanine, T:T11I‘:T11I‘eOI11I1e, 
V:Val:Valine, CICysICysteine, LILeuILeucine, 
YITyFTyrosine, I:Ile:Isoleucine, NIAsnIAsparagine, 
PIProIPrOline, QIGInIGlutamine, FIPheIPhenylaIanine, 
DIAspIAspartic Acid, WITrpITryptOphan, 
E:Glu:Glutamic Acid, M:Met:Methionine, 
KILysILysine, GIGIyIGlycine, RIArgIArginine, 
SISerISerine, HIHisIHistidine. 
In some embodiments, it may be desirable to make muta 
tions in the active site of a polypeptide, e.g., to reduce or 
completely eliminate deformylase activity. Mutations that 
Will reduce or completely eliminate the activity of a particular 
protein Will be apparent to those of skill in the art. For 
example, the amino acids identi?ed in Table 1 could be 
mutated in order to reduce or eliminate the binding activity of 
Wild-type Arabidopsis Zhaliana peptide deformylase or the 
sequence of amino acids set forth in SEQ ID NO: 1. 
The amino acid residue Cys (C) is unusual in that it can 
form disul?de bridges With other Cys (C) residues or other 
sulfhydryl-containing amino acids (“cysteine-like amino 
acids”). The ability of Cys (C) residues and other cysteine 
like amino acids to exist in a polypeptide in either the reduced 
free iSH or oxidiZed disul?de-bridged form affects Whether 
Cys (C) residues contribute net hydrophobic or hydrophilic 
character to a polypeptide. 
While in most instances the amino acids of Wild-typeAra 
bidopsis Zhaliana peptide deformylase or the sequence of 
amino acids set forth in SEQ ID NO:1 Will be substituted With 
genetically-encoded amino acids, in certain circumstances 
mutants may include genetically non-encoded amino acids. 
Alternatively, in instances Where the mutant Will be prepared 
in Whole or in part by chemical synthesis, virtually any non 
encoded amino acids may be used, ranging from D-isomers of 
the genetically encoded amino acids to non-encoded natu 
rally-occurring natural and synthetic amino acids. 
Conservative amino acid substitutions for many of the 
commonly knoWn non-genetically encoded amino acids are 
Well knoWn in the art. Conservative substitutions for other 
non-encoded amino acids can be determined based on their 
physical properties as compared to the properties of the 
genetically encoded amino acids. 
In some instances, it may be particularly advantageous or 
convenient to substitute, delete from and/ or add amino acid 
residues to wild-typeArabidopsis Zhaliana peptide deformy 
lase or the sequence of amino acids set forth in SEQ ID NO:1 
in order to provide convenient cloning sites in cDNA encod 
ing the polypeptide, to aid in puri?cation of the polypeptide, 
etc. Such substitutions, deletions and/or additions that do not 
substantially alter the three dimensional structure of the 
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7 
native Arabidopsis Zhaliana peptide deformylase or the 
sequence of amino acids set forth in SEQ ID NO11 Will be 
apparent to those having skills in the art. These substitutions, 
deletions and/ or additions include, but are not limited to, His 
tags, BirA tags, intein-containing self-cleaving tags, maltose 
binding protein fusions, glutathione S-transferase protein 
fusions, antibody fusions, green ?uorescent protein fusions, 
signal peptide fusions, biotin accepting peptide fusions, and 
the like. 
Mutations may also be introduced into a polypeptide 
sequence Where there are residues, e.g., cysteine residues, 
that interfere With crystallization. Such cysteine residues can 
be substituted With an appropriate amino acid that does not 
readily form covalent bonds With other amino acid residues 
under crystallization conditions; e. g., by substituting the cys 
teine With Ala, Ser or Gly. Any cysteine located in a non 
helical or non-beta-stranded segment, based on secondary 
structure assignments, are good candidates for replacement. 
It should be noted that the mutants contemplated herein 
need not exhibit deformylase activity. Indeed, amino acid 
substitutions, additions or deletions that interfere With the 
binding activity of Wild-type Arabidopsis Zhaliana peptide 
deformylase or the sequence of amino acids set forth in SEQ 
ID NO11 are speci?cally contemplated by the invention. Such 
crystalline polypeptides, or the atomic structure coordinates 
obtained therefrom, can be used to provide phase information 
to aid the determination of the three-dimensional X-ray struc 
tures of other related or non-related crystalline polypeptides. 
Also contemplated are homologs of the Arabidopsis 
Zhaliana peptide deformylase. The present invention provides 
a computer-assisted method for homology modeling an Ara 
bidopsis thaliana peptide deformylase homolog including: 
aligning the amino acid sequence of anArabidopsis Zhaliana 
peptide deformylase homolog With the amino acid sequence 
of Arabidopsis Zhaliana peptide deformylase SEQ ID N011 
and incorporating the sequence of the Arabidopsis Zhaliana 
peptide deformylase homolog into a model of Arabidopsis 
Zhaliana peptide deformylase derived from structure coordi 
nates set forth in Table 1 to yield a preliminary model of the 
Arabidopsis Zhaliana peptide deformylase homolog; subject 
ing the preliminary model to energy minimization to yield an 
energy minimized model; remodeling regions of the energy 
minimized model Where stereochemistry restraints are vio 
lated to yield a ?nal model of the Arabidopsis Zhaliana pep 
tide deformylase homolog. 
As used herein, the term “homolog” refers to the polypep 
tide molecule or the nucleic acid molecule Which encodes the 
polypeptide, or a functional domain from said polypeptide 
from a ?rst source having at least about 30%, 40% or 50% 
sequence identity, or at least about 60%, 70% or 75% 
sequence identity, or at least about 80% sequence identity, or 
more preferably at least about 85% sequence identity, or even 
more preferably at least about 90% sequence identity, and 
most preferably at least about 95%, 97% or 99% amino acid 
or nucleotide sequence identity, With the polypeptide, encod 
ing nucleic acid molecule or any functional domain thereof, 
from a second source. The second source may be a version of 
the molecule from the ?rst source that has been genetically 
altered by any available means to change the primary amino 
acid or nucleotide sequence or may be from the same or a 
different species than that of the ?rst source. Homology mod 
eling is further discussed beloW. 
Accordingly, provided herein are crystalline forms of a 
plant peptide deformylase. Referring to FIG. 1A, limited 
trypsinolysis creates a core protein that retained activity and 
remained soluble in the absence of high salt concentrations. 
Analysis of Wild-type and proteolyzed AtDEF2 on an 8-16% 
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gradient SDS-PAGE. Trypsinolysis produces a truncated 
DEF2 With a mobility shift corresponding to a 3 kDa loss in 
molecular mass from AtDEF2, a 24.598 kDa enzyme. The 
truncated DEF2, Which loses its hexahistidyl sequence, Was 
subsequently separated from undigested DEF2 by loading the 
digested sample onto a HiTrap® a?inity column (Amersham 
Pharmacia) and collecting the ?oWthrough. Undigested 
DEF2 remained bound to the column. Referring to FIG. 1B, 
the amino acid sequence of the truncated DEF2 polypeptide is 
provided. 
It is understood that the term “crystalline form” includes a 
polypeptide associated With a plant peptide deformylase can 
include just the polypeptide, or the polypeptide complexed 
With a metal, a ligand, or any other chemical entity suitable 
for crystallization With the polypeptide. An exemplary 
polypeptide includes Arabidopsis Zhaliana peptide deformy 
lase, or fragments thereof, suitable for crystallization. Such 
fragments include optionally, the crystal may include a coor 
dinated metal ion selected from the group of consisting of Fe, 
Zn, Ni, or combinations thereof. Thus, “crystalline form” and 
“crystal” refer to a composition comprising a polypeptide 
complex in crystalline form. The term “crystal” includes 
native crystals, heavy-atom derivative crystals and poly-crys 
tals. “Native Crystal” refers to a crystal Wherein the polypep 
tide complex is substantially pure. 
Referring to FIG. 2A, the crystal structure of DEF2 Was 
determined by molecular replacement and re?ned to a reso 
lution of 2.7 A. “Molecular Replacement” refers to the 
method of calculating initial phases for a neW crystal of a 
polypeptide Whose structure coordinates are unknown by ori 
enting and positioning a polypeptide Whose structure coordi 
nates are known Within the unit cell of the neW crystal so as to 
best account for the observed diffraction pattern of the neW 
crystal. Phases are then calculated from the oriented and 
positioned polypeptide and combined With observed ampli 
tudes to provide an approximate Fourier synthesis of the 
structure of the polypeptides comprising the neW crystal 
(Jones et al., 1991, Acta Crystallogr. 471753-70; Brunger et 
al., 1998, Acta Crystallogr. D. Biol. Crystallogr. 541905-21). 
The overall fold of the enzyme resembles the 0t+[3 confor 
mation of knoWn bacterial peptide deforrnylases, With an 
r.m.s deviation of about 1.04 A on main chain atoms relative 
to the E. coli enzyme. The largest differences occur in the 
orientation of the C-terminal helix (helix 3) and the confor 
mation of the loop betWeen [3 strands 2 and 3, Which form part 
of the ?ve-stranded central sheet. Motif I, II and III are col 
ored blue, green and pink, respectively. The active site metal, 
modeled as zinc due to the conditions of crystallization, is a 
space-?lled sphere in the middle of the structure. Referring to 
FIG. 2B, a slab vieW of the ribbon representation of trypsi 
nolyzed AtDEF2 highlighting the active-site-metal binding 
ligands (1 Cys and 2 His) from motifs II and III, respectively 
(EGCLS (SEQ ID NO: 2) and QHEXXH (SEQ ID NO: 3)) is 
provided. As used herein, the term “active site” refers to 
regions on a protein or a structural motif of a protein that are 
directly involved in the function or activity of the peptide 
deformylase. 
As used herein, the terms “binding site” or “binding 
pocket” refer to a region of a polypeptide or a molecular 
complex comprising the polypeptide that, as a result of the 
primary amino acid sequence of the polypeptide and/or its 
three-dimensional shape, favorably associates With another 
chemical entity or compound including ligands or inhibitors. 
The crystalline form can include the tetragonal space group 
symmetry P4l212 and includes a unit cell having dimensions 
a, b, and c; Wherein a is about 40 A to about 60 A, b is about 
40 A to about 60 A, and c is about 120 A to about 160 A; and 


































